StreetInsider.com News Articles

Kiora Pharmaceuticals names new clinical development chief

Tue, 08 Sep 2026 07:02:20 -0400

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced the appointment of Keith J. Lane as Executive Vice President of Clinical Development and Regulatory Affairs, according to a company statement.

Lane joins Kiora from Ora, Inc., an ophthalmology-focused clinical research organization, where he served as Chief Scientific Officer. During his tenure at Ora, he oversaw clinical operations and regulatory strategy for more than 60 ophthalmic trials, including 12 global Phase 3 pivotal studies that supported three new drug application submissions and one biologics license application submission.

Lane holds an MBA in health sector management from Boston University's Questrom School of Business and a Bachelor of

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

Tue, 08 Sep 2026 07:00:00 -0400

Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora's pipeline and new asset opportunities

Encinitas, California--(Newsfile Corp. - September 8, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of experience in ophthalmic drug development, clinical development and operations and regulatory strategy across Phase 1 through Phase 4 clinical trials.

"Keith has substantial experience supporting U.S. and global clinical programs across retinal

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

Tue, 08 Sep 2026 07:00:00 -0400

Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora's pipeline and new asset opportunities

"Keith has substantial experience supporting U.S. and global clinical programs across retinal

Form 8-K KIORA PHARMACEUTICALS For: Aug 19

Wed, 19 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260819/26947090.html

Form 8-K KIORA PHARMACEUTICALS For: Aug 19

Wed, 19 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260819/26947090.html

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Wed, 19 Aug 2026 07:00:00 -0400

Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies. Under the agreement, Kiora will receive a $1 million upfront payment and is eligible to receive development and regulatory milestone payments, as well as royalties on future sales of KIO-301 in South Korea.

"KIO-301 is a molecular photoswitch designed to restore light sensitivity in degenerated retinal cells through a

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Wed, 19 Aug 2026 07:00:00 -0400

"KIO-301 is a molecular photoswitch designed to restore light sensitivity in degenerated retinal cells through a

Form SCHEDULE 13G/A KIORA PHARMACEUTICALS Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260814/26932513.html

Form SCHEDULE 13G/A KIORA PHARMACEUTICALS Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260814/26932513.html

Form SCHEDULE 13G/A KIORA PHARMACEUTICALS Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932142.html

Form SCHEDULE 13G/A KIORA PHARMACEUTICALS Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932142.html

Form SCHEDULE 13G KIORA PHARMACEUTICALS Filed by: PERCEPTIVE ADVISORS LLC

Mon, 10 Aug 2026 11:59:00 -0400

si-local-file:///var/storage/secattach/20260810/26896335.html

Form SCHEDULE 13G KIORA PHARMACEUTICALS Filed by: PERCEPTIVE ADVISORS LLC

Mon, 10 Aug 2026 11:59:00 -0400

si-local-file:///var/storage/secattach/20260810/26896335.html

Kiora Pharmaceuticals (KPRX) Tops Q2 EPS by 17c

Fri, 07 Aug 2026 07:34:27 -0400

Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q2 EPS of ($0.34), $0.17 better than the analyst estimate of ($0.51).

For earnings history and earnings-related data on Kiora Pharmaceuticals (KPRX) click here.

Form 10-Q KIORA PHARMACEUTICALS For: Jun 30

Fri, 07 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260807/26887370.html

Form 10-Q KIORA PHARMACEUTICALS For: Jun 30

Fri, 07 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260807/26887370.html

Form 8-K KIORA PHARMACEUTICALS For: Aug 07

Fri, 07 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260807/26887375.html

Form 8-K KIORA PHARMACEUTICALS For: Aug 07

Fri, 07 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260807/26887375.html

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Fri, 07 Aug 2026 07:00:00 -0400

Encinitas, Califfornia--(Newsfile Corp. - August 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today reported financial results for the second quarter ended June 30, 2026, and provided an update on its clinical pipeline of small-molecule therapies for retinal diseases and its corporate development activities.

Second Quarter 2026 and Recent Highlights

Advanced enrollment in the Phase 2 ABACUS-2 clinical trial of KIO-301 into the higher-dose cohort
Continued enrollment in the higher-dose cohort of the Phase 2 KLARITY clinical trial of KIO-104
Ended the quarter with approximately $16.8 million in cash and short-term investments, providing an expected operating runway into late 2028
Secured a private placement for

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Fri, 07 Aug 2026 07:00:00 -0400

Second Quarter 2026 and Recent Highlights

Advanced enrollment in the Phase 2 ABACUS-2 clinical trial of KIO-301 into the higher-dose cohort
Continued enrollment in the higher-dose cohort of the Phase 2 KLARITY clinical trial of KIO-104
Ended the quarter with approximately $16.8 million in cash and short-term investments, providing an expected operating runway into late 2028
Secured a private placement for

Form 4 KIORA PHARMACEUTICALS For: Jul 01 Filed by: Strem Brian M.

Thu, 02 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260702/26728909.html

Form 4 KIORA PHARMACEUTICALS For: Jul 01 Filed by: Strem Brian M.

Thu, 02 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260702/26728909.html

Form 4 KIORA PHARMACEUTICALS For: Jul 01 Filed by: Tosca Melissa

Thu, 02 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260702/26728920.html

Form 4 KIORA PHARMACEUTICALS For: Jul 01 Filed by: Tosca Melissa

Thu, 02 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260702/26728920.html

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

Thu, 02 Jul 2026 07:00:00 -0400

Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium.

Presentation Details

Date: Thursday, July 9, 2026
Time: 2:30 p.m. Eastern Daylight Time
Live Presentation: Available on Kiora's Investor Relations homepage at ir.kiorapharma.com
Replay: Available for 90 days on Kiora's Investor Relations Events page at ir.kiorapharma.com/news-events/events

About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301